We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cellular Goods Plc | LSE:CBX | London | Ordinary Share | GB00BK964W87 | ORD GBP0.001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.375 | 0.35 | 0.40 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Catalog, Mail-order Houses | 67k | -3.31M | -0.0055 | -0.67 | 2.23M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/9/2021 10:41 | Who are for example buying 6m MGC at an average or 2.1? Losers ? | kirk 6 | |
28/9/2021 10:25 | Losers average losers. | biggest bill | |
28/9/2021 08:11 | Starting to ramp up now. It isn't that long to the launch of the products and some potentially major contract wins.Also Twitter is getting noisier from CBXThis corpse will also have its day soon. | kirk 6 | |
18/9/2021 08:26 | Looks cheap at this price. | sharetalk | |
09/9/2021 10:55 | I hold CBX at a heavy loss. I hold KNB at a heavy loss. I will however carry on executing my plan to average down as they are still relatively new to the arena. Essentially though this could be construed as an off topic post but its not. OCTP = Oxford Cannabinoid Technologies Ltd Same arena as other cannabis stocks = No, not really as these are focussed on medicinal, and have already signed service agreements, and have already secured access to Multi Billion $ market. Unlike KNB, and CBX, OCTP are trading some 50% lower than the IPO price. Yet amazingly appear to have progressed further. In a couple of weeks we will receive their results, and the trading update suggests all is on track with the exception they are fast tracking to market and clinical trials. :-) But, extra exciting is in a few weeks time OCTP will also be tradeable in the USA and we all know the appetite the yanks have for stocks like this. And even better, the listing will not be in the form of a fund raising. Stock will IMO fly. Of course its all subjective and one must do their own research, but of the Cannabis related stocks, OCTP does appear to have a leading edge yet is somewhat overlooked. | whites123 | |
06/9/2021 13:12 | Having reached a low of 6p - 6.1p earlier it looks more than likely we are at a low point. The IPO price was 5p and the highest prices paid about 29p. The interest here has gone from sky-high to into the doldrums | noirua | |
02/9/2021 08:59 | Dipped in today, Fallen too low. Products launch coming in Dec. and spring next year. Buy and hold imo. | andyr42 | |
26/8/2021 09:21 | No signs of any follow through on the back of Mxc run But seeing as the price is so weak I have bought some at 6.68p and will add if it drops nearer 6p Hopefully sell next time it gets to 7.5-9p range | dave4545 | |
18/8/2021 17:56 | An interesting interview on cannabis - Auxly Cannabis Group: CBX: | noirua | |
16/8/2021 09:41 | Meaningful announcement. | sunnysideup1 | |
16/8/2021 09:13 | We also have an all product launch date of Mid-December | ashleyjv | |
16/8/2021 09:08 | This is great news. This deal will bring an extended range of products to the market a year earlier than planned and, in time for the new year buying season. | ashleyjv | |
16/8/2021 07:46 | Excellent news this will be a mid cap by Christmas | kirk 6 | |
16/8/2021 07:23 | 16/08/2021 7:00am UK Regulatory (RNS & others) Cellular Goods (LSE:CBX) Intraday Stock Chart Monday 16 August 2021 RNS Number : 6698I Cellular Goods PLC 16 August 2021 Press release 16 August 2021 Cellular Goods PLC ("Cellular Goods" or "the Company") Multiyear supply agreement signed for launch of ingestible products Cellular Goods (LSE: CBX), a UK-based provider of premium consumer products formulated with lab-made cannabinoids, is pleased to announce a multi-year manufacture and supply agreement with Chanelle McCoy Health Ltd (CMH) bringing forward its launch of a range of clinically-validated ingestible products to Q4 2021. Under the agreement, CMH, a research-led developer of high quality ultra pure cannabinoid (CBD) products that are fully compliant with the new novel food regime, will initially supply three CBD ingestibles which will go on sale under the Cellular Goods brand in the UK, followed by continental Europe in 2022. The deal marks a significant step in Cellular Goods' go-to-market strategy and will accelerate its entry into the market for ingestible wellness products for human consumption by more than a year. These products will be introduced in mid-December at the same time as the Company's inaugural skincare range incorporating cannabigerol (CBG), and ahead of the new season product launches typically made in the wellness sector during the first quarter of a new year. The Company will initially sell the ingestible range exclusively through its new ecommerce website, which is in the latter stages of build and deployment. A third line-up of "movement" products for both the athletic and everyday muscle recovery market is due to be launched in Spring 2022. Key benefits of the deal include: -- Immediate entry into the most developed market segment with early revenue generation opportunity. -- Expands Cellular Goods' branded product range into a complementary market segment. -- Provides access to a range of novel-food regulation compliant products which are ready for launch. -- Reduced upfront R&D expenditure for market entry in ingestibles. -- Opportunity for future product development and research collaborations through access to compliant ultra pure CBD and pharmaceutical expertise. At launch the ingestible range will comprise a tincture, spray, and capsules covering the most popular modes of consumption. These have already passed extensive quality, safety and stability tests, comply with novel foods regulations in the UK and EU and are certified under Good Manufacturing Practice (GMP) standards. They contain lab-made CBD obtained through a GMP-certified process whereby naturally derived raw materials are converted to non-psychoactive ultra pure CBD that is bioidentical to plant-derived CBD but devoid of the many contaminants commonly found in plant-extracts, including pollutants, toxins, terpenes, heavy metals, pesticides, and psychoactive substances. -- According to the Association for the Cannabinoid Industry (ACI) the UK has the world's most developed regulatory framework for legal cannabinoids and this market is estimated to be worth GBP690 million in 2021, making it the second largest in the world after the US. -- The market for ingestible CBD products has seen strong growth following the European Commission's ruling that CBD is not considered a narcotic under the United Nations Single Convention on Narcotic Drugs of 1961. -- Similarly, the World Anti Doping Agency has removed CBD from its list of prohibited substances, enabling use by professional and amateur athletes. The World Health Organization has also stated that CBD is "generally well-tolerated with a good safety profile". Alexis Abraham, Cellular Goods' Chief Executive Officer, said: "Chanelle McCoy Health was founded by pharmaceutical industry veterans who share our vision that consumers have a right to expect products which are safe, pure, clean and green; something lab-made cannabinoids alone can guarantee. Through this partnership we will be introducing consumers to novel food compliant CBD ingestibles that will complement our CBG skincare range. As a result we will launch this year with both CBD and CBG and two best in class product ranges; one of which is substantially earlier than we expected." Lady McCoy, Chief Executive and Co-Founder of Chanelle McCoy Health, added: "We are very excited to announce this commercial supply agreement of our ultra pure CBD. Consumers are searching for safe, certified, and reputable CBD products that are backed by clinical studies. This partnership will provide them choice and access to quality-assured CBD products containing 0% THC, an illegal narcotic, and free from toxins and pollutants. Cellular Goods and Chanelle McCoy Health are aligned in our pursuit to help break the stigma of CBD, educate and set the benchmark for the CBD industry." | david gruen | |
16/8/2021 07:21 | Great news today, progress indeed Gla | andyview | |
10/8/2021 09:04 | Bought a few today | ashleyjv | |
08/8/2021 22:36 | Respect Kirky | peaky00 | |
08/8/2021 22:35 | Could get above 10p this week | kirk 6 | |
08/8/2021 21:40 | Are u mad Hodhasharon? | peaky00 | |
08/8/2021 21:08 | It's going below 1p | costax1654x | |
05/8/2021 12:04 | I've put all that I could salvage from SYME into CBX. | henrythegerbil | |
02/8/2021 23:28 | That is what's been holding it back | ultimatejustice9 | |
02/8/2021 08:14 | Scam shareJohn story has been rinsing aim investors allOver the showNext time you see his name in a placing you know the guy will be dumping as fast as he can | bigberty99 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions